The U.S.
FDA has sent a new batch of warning letters to telehealth firms that allegedly made false and misleading claims about low-cost compounded versions of GLP-1 drugs, the popular class of weight-loss therapies marketed by Novo Nordisk (NVO Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities
Subscribe to Newsletters To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser